Gregory T. Lucier was Chairman and CEO of Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific for $15.4 billion in 2014. During Mr. Lucier’s 11-year tenure, he led the company from a small start-up known as Invitrogen in 2003 and directed the acquisition and merger of Invitrogen with Applied Biosystems in 2008 into the renamed Life Technologies. By 2008, he had transformed the organization into a global, world-leading biotechnology firm with 50,000 products, 10,000 employees and nearly $4 billion in sales in more than 180 countries.
Mr. Lucier was responsible for fostering a culture of excellence at Life Technologies, and applied his 25+ years of strategic management experience to help champion an era of personalized medicine.
Gregory C. Critchfield, M.D.
Dr. Critchfield is chairman, president and CEO of Sera Prognostics, Inc. and the former president of Myriad Genetic Laboratories, Inc. He led its transformation into one of the world’s leading molecular diagnostics companies. Under his direction, Myriad Genetic Laboratories launched seven novel molecular diagnostic products across a variety of technology platforms, posting 52 percent compounded annual revenue growth from 1998 through 2010. Prior to joining Myriad, Dr. Critchfield was Chief Medical & Science Officer at Quest Diagnostics, Inc., overseeing medical affairs and innovation activities during its transition from Corning Clinical Laboratories.
He has also served on the faculty of three medical schools — University of Minnesota, Wayne State University, and Duke University — and was a practicing clinical pathologist with Intermountain Healthcare.
Andrew ElBardissi, M.D.
Dr. Andrew ElBardissi is an investor on the Private Transaction team at Deerfield Management. Prior to joining Deerfield, Dr. ElBardissi held roles as an early stage life-sciences investor and as an Investment Banker at J.P. Morgan’s Healthcare practice. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ), has over 30 publications in leading peer-reviewed scientific journals, and has presented his research at numerous medical and surgical conferences.
Dr. ElBardissi’s board memberships include Acutus, Farapulse, SentreHeart, Sollis Therapeutics, vWave, Conventus, Neochord, and Incarda Therapeutics.
Kim Kamdar, Ph.D.
Kim Kamdar joined Domain Associates in 2005 and became a partner in 2011. With a background in small molecule drug discovery, Dr. Kamdar has been involved in cutting-edge therapeutic start-ups, using her expertise to identify companies with promising molecular and companion diagnostics that support personalized medicine.
Her present board memberships include Ariosa Diagnostics, Epic Sciences, Lithera, Obalon Therapeutics, ROX Medical, Sera Prognostics, Sonexa Therapeutics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. She was also involved with Corthera until its sale to Novartis in February 2010 and BiPar Sciences until its acquisition by Sanofi-Aventis in April 2009.
Prior to Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capita and a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology.
Dr. Kamdar has authored ten papers and received seven patents. She completed her B.A. at Northwestern University and her Ph.D. in biochemistry and genetics at Emory University. Dr. Kamdar serves as an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine and the Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies. She is also a board member of San Diego's CONNECT Foundation and the Hastings Center.
Charles Kennedy, M.D.
Dr. Charles Kennedy has a proven track record as a visionary healthcare leader and has been recognized as an expert in health information technology. Currently, Dr. Kennedy is managing partner at Blue Ox Healthcare Partners, leading their efforts to identify companies with innovations in healthcare services, technology, and devices which can enable providers and health plans to optimize value-based health care strategies.
Prior to joining Blue Ox, Dr. Kennedy held multiple executive positions with Aetna, including Vice President and Chief Medical Officer for Clinical Integration and Chief Population Officer, where he led and implemented population health management programs. Additionally, Dr. Kennedy has served in several executive leadership positions with WellPoint Inc., CareAssured.com, and Blue Shield of California.
Dr. Kennedy’s vast experience and leadership have earned him multiple board appointments and he currently serves as a Ventures Advisory Group Board member with Rethink Health and as an Insurance Industry representative with Health Information Technology Policy Committee.
Dr. Kennedy completed his Bachelor of Science in Genetics at the University of California at Berkeley. He holds an M.D. in Internal Medicine from the University of California at Los Angeles and his MBA in Corporate Strategy and Health Care Economics from Stanford University.
Every time Epic’s AR-V7 test is administered the healthcare system saves about $15,000 per year of life extended. In other words approximately $7,000 to $9,000 per patient tested.
Of the roughly 30 million cells in a typical blood sample, about 5 are cancer cells on their way to form tumors elsewhere in the body. Modern cancer diagnostics technology can't see them.
We spend about $100 billion a year on cancer drugs. But because we’re not matching the right drug to the right patient and their disease in a personalized way, about 3/4ths of that drug spend is wasted.
The Epic approach answers a critical question for a doctor: When is a patient resistant? By answering that question accurately and precisely we increase patient life and save the system money at the same time.
Today, Epic Sciences is embedded in clinical trials with 48 leading producers of oncology drugs and 35 of the top academic cancer hospitals.
It takes only 7 minutes to acquire an entire image of 6 million stained cells on a 1 x 3 slide. Then that image, which is about 20GB of data, gets sent up to the cloud where the algorithms run and find the rare events in about 2 more minutes.